Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vasomotor Symptoms Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes

NCT00992914
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
Sympathetic nerve block with 1% lidocaine 1-2 ml, Superficial subcutaneous injection
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 2 Interventional

FP-101 for the Treatment of Hot Flashes in Postmenopausal Women

NCT03285672
View directory record Official record
Conditions
Hot Flashes
Interventions
FP-101, Placebo Comparator
Drug
Lead sponsor
Fervent Pharmaceuticals
Industry
Eligibility
40 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 3, 2026, 9:33 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

NCT07042516
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
40 Years to 62 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 4 Interventional

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

NCT00160173
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Estrogel, Placebo
Drug · Other
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

NCT05042362
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

NCT03640754
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
G-CSF, Placebo/Saline
Biological · Other
Lead sponsor
MenoGeniX, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Womens Study to Alleviate Vasomotor Symptoms

NCT04587154
View directory record Official record
Conditions
Hot Flashes
Interventions
low-fat vegan diet with 1/2 cup soybeans daily
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

NCT04003155
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
72
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms

NCT06787443
View directory record Official record
Conditions
Menopausal Symptoms
Interventions
Placebo, Dietary Supplement with Proprietary Herbal Extract Blend and GABA
Dietary Supplement
Lead sponsor
Olly, PBC
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Not applicable Interventional

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

NCT07408115
View directory record Official record
Conditions
Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions
JDS-HF3.0
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

NCT00446199
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes
Interventions
0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 3, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional

Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)

NCT07834463
View directory record Official record
Conditions
Menopause, Hot Flashes
Interventions
Shatavari (Asparagus racemosus) Extract, Placebo
Dietary Supplement · Other
Lead sponsor
India Glycols Ltd
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

NCT04209543
View directory record Official record
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol, Placebo, Progesterone
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
65
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Yoga on Objective and Subjective Menopausal Hot Flashes

NCT01073397
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Yoga
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
45 Years to 58 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 3, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hot Flashes and Neurovascular Function in Women

NCT05193968
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor System; Labile
Interventions
Sympathoexcitatory stressors, Sodium Nitroprusside, Acetylcholine, Terbutaline, Norepinephrine
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

NCT00786188
View directory record Official record
Conditions
Hot Flashes
Interventions
Brisdelle (paroxetine mesylate), Sugar pill
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
41 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Lake Worth, Florida • Naples, Florida • Greensboro, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 3, 2026, 9:33 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

NCT02653417
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes
Interventions
RAD1901, Placebo
Drug · Other
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

NCT01178892
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Placebo, Omega-3, Yoga, Exercise, Usual Activity
Dietary Supplement · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

NCT05325775
View directory record Official record
Conditions
Post-menopausal Vasomotor Symptoms
Interventions
ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo
Drug
Lead sponsor
Acer Therapeutics Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 3, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional

Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women

NCT07751029
View directory record Official record
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions
Interventions
Haelan 951
Dietary Supplement
Lead sponsor
Spectrum Clinical Research, LLC
Network
Eligibility
45 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study - Impact of Traditional Acupuncture on Menopause

NCT00950482
View directory record Official record
Conditions
Menopause
Interventions
TA, AA, WC
Procedure · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

NCT01101841
View directory record Official record
Conditions
Hot Flashes
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Not applicable Interventional Results available

Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women

NCT02040532
View directory record Official record
Conditions
Menopause, Hot Flashes, Vasomotor Disturbance
Interventions
Gabapentin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 3, 2026, 9:33 PM EDT
Completed Phase 2 Interventional

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

NCT06385795
View directory record Official record
Conditions
Menopause Syndrome, Menopause, Hot Flashes
Interventions
NOE-115
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 3, 2026, 9:33 PM EDT